Ursodiol (Synonyms: NSC 683769, UDCA, Ursodiol) |
| Katalog-Nr.GC13363 |
Ursodiol (Ursodeoxycholat) ist eine sekundÄre GallensÄure, die bei der Umwandlung von (Cheno)desoxycholsÄure durch Darmbakterien entsteht und als SchlÜsselregulator fÜr die IntegritÄt der Darmbarriere fungiert und fÜr den Fettstoffwechsel unerlÄsslich ist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 128-13-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ursodiol (UDCA) is a secondary bile acid derived from the 7α/β isomerization of the primary bile acid chenodeoxycholic acid (CDCA) by microorganisms. Ursodiol can be used in the study of various liver diseases and gastrointestinal diseases. Ursodiol has cytoprotective, anti-apoptotic, membrane-stabilizing, antioxidant and immunomodulatory effects[1-3].
Ursodiol can inhibit the viability of HepG2 and BEL7402 cells with IC50 of 0.92 mmol/L and 0.86 mmol/L, respectively, but Ursodiol has no effect on the viability of normal hepatocytes L-02. After Ursodiol (1.0 mmol/L) treatment, the apoptosis rate of HepG2 and BEL7402 cells was significantly increased in a concentration-dependent manner, whereas the apoptosis rate of L-02 cells did not change significantly.Ursodiol inhibits Bcl-2 expression and promotes Bax expression [2].
Mice treated with low and high doses (50 and 450 mg/kg/day) of Ursodiol showed significant weight loss, whereas 150 mg/kg/day had no significant effect on mouse body weight. After 21 days of ursodiol treatment, the microbial community structure and bile acid pool in the ileum and cecum contents and feces of mice were significantly changed compared with those before treatment. Ursodeoxycholic acid (UDCA), Tauroursodeoxycholic acid (TUDCA), Glycoursodeoxycholic acid (GUDCA) and Lithocholic acid (LCA) levels were significantly elevated in the ileum of mice treated with Ursodiol 450 mg/kg[1]. Ursodiol treatment at 416 mg/kg reduces SARS-CoV-2 transmission in a Syrian golden hamster SARS-CoV-2 infection model[4].
References:
[1]Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021 Feb 18;16(2):e0246161.
[2] Liu H, Qin CY, Han GQ, Xu HW, Meng M, Yang Z. Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J Gastroenterol. 2007 Mar 21;13(11):1652-8.
[3] Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.
[4] Brevini T, Maes M, Webb G J, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2[J]. Nature, 2023, 615(7950): 134-142.
| Cell experiment [1]: | |
Cell lines | Hepatoma cells BEL7402 and HepG2 and normal liver cells L-02 |
Preparation Method | Hepatoma cells BEL7402 and HepG2 and normal liver cells L-02 were treated with Ursodiol at concentrations ranging from 0.05mmol/L to 1.0mmol/L, and the cell growth inhibition rate was detected by MTT method at 48 hours, 72 hours and 96 hours. |
Reaction Conditions | 0.05 mmol/L-1.0 mmol/L, 48,72 and 96 h |
Applications | Ursodiol can inhibit the viability of HepG2 and BEL7402 cells. After 48 hours of Ursodiol treatment, the IC50 values of HepG2 and BEL7402 were 0.92 mmol/L and 0.86 mmol/L, respectively. |
| Animal experiment [2]: | |
Animal models | C57BL/6J wildtype mice |
Preparation Method | Five-week-old C57BL/6J WT mice (male and female) were treated with three different doses of Ursodiol (50, 150 and 450 mg/kg) for 21 days, and the mice were weighed daily during the experimental period. |
Dosage form | 50, 150 and 450 mg/kg/day, 21 days, i.g. |
Applications | Compared with the control mice, the mice in the 50 and 450 mg/kg Ursodiol treatment groups continued to lose weight within one week of Ursodiol administration, and there was no significant difference in the body weight of the mice in the 150 mg/kg Ursodiol treatment group. |
References: | |
| Cas No. | 128-13-2 | SDF | |
| Überlieferungen | NSC 683769, UDCA, Ursodiol | ||
| Chemical Name | (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | ||
| Canonical SMILES | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C | ||
| Formula | C24H40O4 | M.Wt | 392.57 |
| Löslichkeit | ≥ 16mg/mL in DMSO | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5473 mL | 12.7366 mL | 25.4732 mL |
| 5 mM | 0.5095 mL | 2.5473 mL | 5.0946 mL |
| 10 mM | 0.2547 mL | 1.2737 mL | 2.5473 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *